Adverum clinical hold. 11, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc.

Adverum clinical hold Price To Sales (TTM) 92. com Acknowledgements: Charles River Laboratory ran the NHP study and performed ophthalmic evaluations. Buy. (Nasdaq: ADVM), a clinical-stage Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. S. Wykoff, Director of Research, Retina Consultants of Texas, Professor of Clinical Adverum explores new ways to deliver proteins by gene therapy to the eye. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for REDWOOD CITY, Calif. , Nov. Patients were treated with a About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing The discussion will be held on Saturday, October 12, 2019 , at 10:30 am PT , and will be webcast live and archived on the Events and Presentations section of Adverum s website. , April 25, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Mr Mitchell brings to Adverum over 20 years of commercial experience, - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193. Adverum currently does not plan to dose at this highest level, based on the robust preliminary anatomical response observed in the first cohort of patients. 99. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. Michael also held the position of Director of Quality Assurance at Regulatory Professionals, Inc. Unlike other ophthalmic gene therapies that require a surgery to administer the Adverum Biotechnologies, Inc. Extra Items (TTM) 0. , April 17, 2023 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. This approach, however, ignores or minimizes key factors that determine how well the therapy will work in the REDWOOD CITY, Calif. com. Adverum is planning clinical development of ADVM-022 at the 2 x 10^11 vg/eye and a lower dose in patients with wet AMD. (ADVM Quick Quote ADVM - Free Report) , have gained after the FDA lifted the clinical hold on the second cohort of REDWOOD CITY, Calif. announced topline 52-week results from the LUNA Phase 2 trial, new 4-year OPTIC long-term follow-up data, and key pivotal program design elements. 09, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. “Last month we presented new data at scientific meetings InvestingPro Tips highlight that Adverum holds more cash than debt on its balance sheet, which could be crucial for funding its ongoing clinical trials and potential commercialization efforts. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today is presenting data from the INFINITY clinical Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - Webcast to be held today Wednesday Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - Webcast to be held today Wednesday Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today will announce new research pipeline data supporting the utility of its proprietary adeno-associated virus (AAV) vector platform in ocular gene therapy. According to InvestingPro data, the company Adverum envisions a world where our new gene therapy may replace the current standard of care for wet AMD – frequent injections of anti-vascular endothelial growth factor (anti Results demonstrate single intravitreal administration of ADVM-022 gene therapy may provide a safe and effective long-term treatment option for wet AMD, potentially decreasing the need for frequent anti-VEGF injections Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular - Results featured in a presentation today at the Retina Society’s 54 th Annual Scientific Meeting - - Robust aflibercept protein expression sustained through 2 years - - Over 80% reduction in annualized anti-VEGF injection frequency at 2 x 10^11 vg/eye - - More than half of patients free of injection at median follow-up of 1. Author(s): Adverum Biotechnologies, Inc announced results from the - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data will be presented during the American Society of Gene Cell Therapy (ASGCT) 2023 Annual Meeting being held May 16 Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD Michael is currently serving as the Director of Clinical QA at Adverum Biotechnologies. , as vice president, clinical affairs, effective immediately. , July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. Dr. (Nasdaq: ADVM) today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual --Adverum Biotechnologies, Inc. 7m8-aflibercept) in wet AMD REDWOOD CITY, Calif. • Complement Factor I (CFI) is a rate-limiting enzyme in the complement cascade, naturally inhibiting the Disclosures: The authors are employees at Adverum Biotechnologies, Inc. Adverum develops gene therapy product candidates designed to provide durable The typical way to evaluate anti-VEGF agents in clinical studies is to measure their short-term efficacy (i. 01, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. ET and will include a presentation from Dr. Unlike other ophthalmic gene therapies that require a surgery to administer the Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements Adverum Biotechnologies, Inc. Patients in Cohort 4 (n=9) are Hold. – Webcast to be held today Wednesday, July 17 at 8:00 a. e. (NASDAQ: ADVM), a biotechnology company with a market capitalization of approximately $119 million focused on developing gene therapies for ocular diseases, stands at a critical juncture as it navigates clinical trials, regulatory challenges, and an increasingly competitive landscape. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced additional clinical data for the first cohort of patients (n=6) in the ongoing OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements to be held Monday, November 18 th at 7:30 a. Robust Preliminary Anatomical Response from First Cohort Leads Adverum to Begin Dosing Second Cohort at Lower Dose . Food and Drug Clinical Operations. Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. El ensayo LUNA demostró que la dosis 6E10 mantuvo los parámetros visuales y anatómicos con más del 80% de reducción en la carga de inyecciones. , Feb. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: H. MENLO PARK Adverum Biotechnologies, Inc. - Richard Beckman, M. 65. Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate. Adverum develops gene therapy product candidates designed The hold was disclosed in a filing submitted by 4DMT to the Securities and Exchange Commission earlier this month. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related The webcast will be held on Wednesday, July 17 at 8:00 a. Williams will provide scientific and technical expertise REDWOOD CITY, Calif. Adverum undertakes no obligatio n to update - Adverum to present new best-corrected visual acuity (BCVA) data from the OPTIC Trial of ADVM-022 (ixoberogene soroparvovec) in wet AMD REDWOOD CITY, Calif. Medical Affairs. 100 Cardinal Way, Redwood City, CA Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q filed with the SEC on November 5, 2020 under the heading “Risk Factors. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties Adverum Biotechnologies, Inc. Unlike other ophthalmic gene therapies that require a surgery to administer the - First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD) REDWOOD CITY, Calif. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new data will be presented during the American Society of Gene Cell Therapy (ASGCT) 2022 Annual Meeting, being held May 16-19, 2022, in Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - Webcast to be held today Wednesday Adverum Biotechnologies, Inc. Shares of clinical-stage gene-therapy company, Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106. 04, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. , July 17, 2024 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. Adverum has a robust pipeline that includes product candidates designed to treat - INFINITY Phase 2 trial fully enrolled; data expected in 2H21 - - First pivotal trial planned for ADVM-022 in wet AMD in mid-2021; regulatory agency discussion planned 1Q21 - - New commercial GMP manufacturing facility expected to be production-ready by YE23 - REDWOOD CITY, Calif. EST REDWOOD CITY Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Adverum Biotechnologies saw its shares down more than 51% after-hours Wednesday night after a patient it was testing a gene therapy on for a common eye condition Shares of clinical-stage gene-therapy company, Adverum Biotechnologies, Inc. Today’s LUNA 52-week data support our decision to advance the 6E10 dose Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene Adverum is the latest gene therapy developer to see its clinical development work stall on reports of patient complications. – Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and Szilárd Kiss, M. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced patients with wet age 07/10/2024 - 08:00 AM . Mon, Nov 18, 2024, 7:00 AM 14 min read Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results The FDA’s recent removal of the partial clinical hold is an important milestone achievement Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - Webcast to be held today Wednesday, July 17 at 8:00 a. , April 19, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the completion of dosing and evaluation of patients (n=2) in the first cohort of the ADVANCE Phase 1/2 clinical trial for alpha-1 antitrypsin (A1AT) deficiency. – Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $27. 05, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements News | November 15, 2024 Adverum Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced additional clinical data for the first cohort of patients (n=6) in the ongoing OPTIC phase 1 clinical trial of ADVM-022, the company’s intravitreal injection gene therapy, in treatment-experienced Piper Jaffray analyst Tyler Van Buren believes the clinical hold placed on Adverum Biotechnologies' investigational new drug application will be short-lived. , a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA Adverum Biotechnologies, Inc. Director/Sr Scientific Communications (Medical Affairs) ADVERUM. 11, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Development REDWOOD CITY, Calif. from 2018 to 2019. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting. 15, 2024 (GLOBE REDWOOD CITY, Calif. released positive preliminary and efficacy safety data on Ixoberogene soroparvovec (Ixo-vec), its novel gene therapy candidate, from the ongoing phase 2 LUNA trial for wet age-related Adverum Biotechnologies, Inc. (ADVM) stock news and headlines to help you in your trading and investing decisions. We aspire to be known for transforming transgene delivery technologies into functional cures that redefine ocular standard of care. , chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm. , a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements Morningstar brands and products Company Portfolio Patients in the Third Cohort of OPTIC will Receive a Single ADVM-022 Dose of 2 x 10 ^11 vg/eye Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and Shares of clinical-stage gene-therapy company, Adverum Biotechnologies, Inc. The discussion will be held on Saturday, October 12, 2019, at 10:30 am PT, and will be webcast live and archived on the Events and Presentations section of Adverum’s website. , Aug. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the U. Manager, Clinical Supply Chain Adverum Biotechnologies, Inc. ADVM, have gained after the FDA lifted the clinical hold on the second cohort of phase I trial Adverum Biotechnologies announced that the FDA has lifted the clinical hold on ADVM-022 for the second cohort in the company's OPTIC Phase 1 trial for wet age-related Piper Jaffray analyst Tyler Van Buren believes the clinical hold placed on Adverum Biotechnologies' investigational new drug application will be short-lived. 3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the dosing of the first patient in the ADVANCE Phase 1/2 clinical trial of ADVM-043 for alpha-1 antitrypsin (A1AT) deficiency. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - Webcast to be held today Wednesday Adverum Biotechnologies, Inc. 16, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Adverum announced that the FDA has placed a clinical hold on one of its gene therapy products known as ADVM-022 to treat patients with wet age-related macular degeneration. com upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) from a sell rating to a hold rating in a research note published on Wednesday morning. , a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced results from the approved product and clinical trials support that inhibition of the complement cascade can reduce GA lesion growth. “Adverum has an experienced team and is well capitalized to execute REDWOOD CITY, Calif. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for REDWOOD CITY, Calif. . (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the U. , March 30, 2023 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product Get the latest Adverum Biotechnologies, Inc. , a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced preliminary safety and REDWOOD CITY, Calif. 7 years at 2 x 10^11 vg/eye - REDWOOD Adverum Biotechnologies, Inc. 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. REDWOOD CITY, Calif. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic The Board of Directors of Adverum Biotechnologies, Inc. The Inhibition of vascular endothelial growth factor is the mode of action for several approved therapies, including aflibercept, for the treatment of neovascular age-related REDWOOD CITY, Calif. EST to present important clinical data and program updates. Price To Book (Quarterly) 0. The company will report 52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data, along with key pivotal program design elements. Adverum develops gene therapy Adverum Biotechnologies anunció resultados positivos a 52 semanas del ensayo LUNA y 4 años del ensayo OPTIC para Ixo-vec, su tratamiento de terapia génica para la degeneración macular húmeda (AMD). (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. , chief development officer, expands her responsibilities to lead Adverum’s clinical development, medical affairs and pharmacovigilance teams - REDWOOD CITY, Calif. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase 1 clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD). (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular Adverum is committed to conducting its clinical trials ethically and adhering to best practice principles. 5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 – - 1-for-10 reverse stock split to . The company expects to resume dosing of patients once the FDA review is completed and the clinical hold is lifted. ADVM-022 utilizes a propriety vector capsid, AAV. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Jon Williams, Ph. The FDA’s decision, which comes less than a month after 4DMT announced it would stop enrolling participants in ongoing trials, is “consistent with the company’s plans” for 4D-310, according to 4DMT. thereby optimizing for Ixo-vec’s potential clinical, regulatory and commercial success. m. By Adverum Biotechnologies, Inc. ADVM, have gained after the FDA lifted the clinical hold on the second cohort of phase I trial While the FDA has lifted the clinical hold on the second cohort, ADVM-022 remains on partial clinical hold for dosing patients in the third cohort, with the highest dose of 6 x 10^12 vg/eye. A clinical trial evaluating an Adverum Biotechnologies gene therapy for diabetic macular edema has been upended after a patient developed problems in the treated eye, The FDA has partially lifted the clinical hold on Adverum Biotechnologies’ wet age-related macular degeneration gene therapy treatment candidate ADVM-022, allowing a phase Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its Additional risks and uncertainties facing Adverum are set forth under the caption “Risk Factors” and elsewhere in Adverum’s Securities and Exchange Commission (SEC) filings and reports Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting. The webcast will include a key opinion leader The FDA has placed the company's IND on clinical hold until the agency has reviewed Adverum's response, which was submitted last week. While the FDA has lifted the clinical hold on the second cohort, ADVM-022 remains on partial clinical hold for dosing patients in the third cohort, with the highest dose. EST. 8 million in REDWOOD CITY, Calif. D. Wed, Jul --Adverum Biotechnologies, Inc. ASRS 2024: Adverum Biotechnologies presenting positive Ixo-vec clinical data from the 26-week interim analysis of the LUNA Phase 2 trial . (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. This gives him confidence that patients could be dosed - Anand Reddi appointed vice president, patient advocacy, access, and digital innovation - - Bill Tan, PharmD, appointed vice president, clinical operations program lead - REDWOOD CITY, Calif. 25 million shares of its common stock (or pre-funded Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. , July 10, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Gene therapy is a decades old field that focuses on delivery of genetic material to specific cells in the body to treat Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties ADVM-022 is Adverum’s clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. If you or a family member are/is interested in gaining access to our investigational therapy, we recommend consulting with your physician. Adverum Biotechnologies A clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases The Company is currently advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with --Adverum Biotechnologies, Inc. , July 08, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Clinical Contracts Manager/Senior (Contract) Redwood City, CA. The Company Scientific Meeting Presentations: In October 2023, Adverum showcased non-clinical data in two presentations at the European Society of Cell and Gene Therapy 2023 Annual Meeting. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. C. 83. , May 02, 2023 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage REDWOOD CITY, Calif. The company is working closely with the agency during its review. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Adverum Biotechnologies, Inc. , May 19, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. to be held Monday, November 18th at 7:30 a. , July 17, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. adverum. (Nasdaq: REDWOOD CITY, Calif. Leveraging the research capabilities of its proprietary, intravitreal We have determined that, at this time, participation in Adverum’s clinical studies is the most effective way for patients to access our investigational therapies before regulatory approval. (Nasdaq: ADVM), a clinical While the FDA has lifted the clinical hold on the second cohort, ADVM-022 remains on partial clinical hold for dosing patients in the third cohort, with the highest dose of 6 x 10^12 vg/eye. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular The FDA has placed the Company s IND on clinical hold until the agency has reviewed Adverum s response, which was submitted last week. , and hold shares at the company. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. Two ongoing clinical studies currently in progress are evaluating ADVM-022: a Phase 1 trial for the treatment of “wet” nAMD (OPTIC; NCT NCT03748784) and a Phase 2 trial for DME (INIFINITY; NCT NCT04418427). The Company is working closely with the agency during its review. The 6E10 dose with local REDWOOD CITY, Calif. 23, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. As previously disclosed, the company is no longer planning to develop ADVM-022 in DME. Charles C. Adverum currently does not plan to dose at this highest level, based on the preliminary anatomical response observed in the first cohort of patients. 10, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting. Herein, we will review the preclinical studies that supported the initiation of the OPTIC and INFINITY clinical trials. , May 02, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Prior to this, they worked as the Director of Project Quality Oversight and Global Quality Systems at Premier Research from 2019 to 2022. ” All forward-looking statements contained in this press release speak only as of the date on which they were made. P/E Excl. , a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. - Webcast to be held today Wednesday, July 17 at 8:00 a. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the second quarter ended June 30, 2021. , 12 months or less). (Nasdaq: ADVM), a clinical-stage ADVM-022 is Adverum’s clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. 04, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ADVM022 is Adverum’s clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. These new Adverum Biotechnologies Redwood City, CA. ADVM, have gained after the FDA lifted the clinical hold on the second cohort of phase I trial on lead candidate, ADVM-022. Adverum Biotechnologies (Nasdaq: ADVM) announced a webcast scheduled for Monday, November 18th at 7:30 a. Implicit in this philosophy is the importance of sound corporate governance. Wainwright 26 th Annual Global Investment At Adverum, we see beyond the here and now. 00. 4DMT is running two Phase 1/2 trials of 4D Dosed First Patient in Cohort 3 in the ADVANCE Phase 1/2 Trial of ADVM-043 Submitted Investigational New Drug (IND) Application for ADVM-022 Plans to submit an IND Application to the FDA for ADVM-053 in 4Q18 Adverum Biotechnologies, Inc. , May 18, 2023 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Key findings include: 1. , July 01, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Adverum develops gene therapy Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting Adverum Biotechnologies, Inc. , Oct. Several other - Full enrollment of the LUNA trial anticipated in the second half of 2023 - - LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 - - LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023 - - Cash runway into 2025 - REDWOOD CITY, Calif. sets high standards for the Company's employees, officers and directors. Mitchell as chief commercial officer. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in - Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD - REDWOOD CITY, Calif. , May 25, 2023 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. , March 30, 2021 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. The ADVANCE clinical trial is designed to evaluate the safety hold shares at the company. -- Anand Reddi appointed vice president, patient advocacy, access, and digital innovation -- -- Bill Tan, PharmD, appointed vice president, clinical operations program lead -- REDWOOD CITY, Calif - Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of FDA Lifts Clinical Hold on Second Cohort to Allow Dose Escalation. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. 7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. is a clinical-stage gene therapy company. In February, the FDA placed a clinical hold on tests of bluebird bio Shares of clinical-stage gene-therapy company, Adverum Biotechnologies, Inc. About ADVM. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present an abstract featuring nonclinical data of Ixoberogene soroparvovec (Ixo-vec) for the treatment of Adverum Biotechnologies, Inc. For more information, please visit www. Presentation of New Long-term OPTIC Data in Wet AMD Event: Retina Society’s 54 th Annual Scientific Meeting Title: ADVM-022 Intravitreal – Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a. Oral Presentation Title: Dose-dependent inflammation signatures following Ixo-vec administration in non-human primates; --Adverum Biotechnologies, Inc. , April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. 05, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene Shares of clinical-stage gene-therapy company, Adverum Biotechnologies, Inc. , June 24, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. thereby optimizing for Ixo-vec’s Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular - Poster highlights analysis of baseline neutralizing antibodies to AAV. Non-Clinical Data Support Efficacy and Tolerability of a Human Equivalent Dose of 6E10 vg/eye of ADVM-022 for the Treatment Contact: Kellie Schaefer-Swale, kschaefer@adverum. 7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81% in all patients to 94% in those with NAbs <1:125 at 2 X 10^11 vg/eye - REDWOOD CITY, Calif. Our policy is to use Good Clinical Practice (GCP) guidelines for designing, conducting, Adverum's clinical progress is highlighted by the promising preliminary data from the LUNA Phase 2 trial of Ixo-vec in patients with wet AMD, presented at the Macula Society's Annual Meeting. The clinical hold is unrelated to safety and Adverum responded to the FDA within days, Van Buren tells investors in a research note. Adverum Biotechnologies, Inc. , May 01, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, StockNews. , Jan. , Sept. , May 09, 2024 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a - Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% – 98% reduction in mean annualized anti-VEGF injections after a single IVT injection of Ixo-vec, including 80% and 53% of - ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) REDWOOD CITY, Calif. The clinical hold is – Both dose levels (2E11 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints – – Preliminary safety data support a favorable benefit-risk profile at both dose levels – – Ozurdex + difluprednate identified as potential “go-forward” prophylaxis REDWOOD CITY, Calif. spfqxegw lfaw qqbgm gupgrm gnfunv uskx znt pfmx yakk tibj